New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 Cision · Oct 1, 2026
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes Cision · Sep 30, 2026
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder Cision · Sep 30, 2026
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress Cision · Sep 30, 2026
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care Cision · Sep 30, 2026
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance Cision · Sep 30, 2026
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes Cision · Sep 29, 2026
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison Cision · Sep 29, 2026
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison Cision · Sep 29, 2026
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program Cision · Sep 29, 2026
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs Cision · Sep 28, 2026
